367 related articles for article (PubMed ID: 26631721)
1. Two Degradation Pathways of the p35 Cdk5 (Cyclin-dependent Kinase) Activation Subunit, Dependent and Independent of Ubiquitination.
Takasugi T; Minegishi S; Asada A; Saito T; Kawahara H; Hisanaga S
J Biol Chem; 2016 Feb; 291(9):4649-57. PubMed ID: 26631721
[TBL] [Abstract][Full Text] [Related]
2. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
Patrick GN; Zhou P; Kwon YT; Howley PM; Tsai LH
J Biol Chem; 1998 Sep; 273(37):24057-64. PubMed ID: 9727024
[TBL] [Abstract][Full Text] [Related]
3. Tissue-type plasminogen activator regulates p35-mediated Cdk5 activation in the postsynaptic terminal.
Diaz A; Jeanneret V; Merino P; McCann P; Yepes M
J Cell Sci; 2019 Feb; 132(5):. PubMed ID: 30709918
[TBL] [Abstract][Full Text] [Related]
4. Cdk5 levels oscillate during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent degradation during S-phase.
Zhang J; Li H; Zhou T; Zhou J; Herrup K
J Biol Chem; 2012 Jul; 287(31):25985-94. PubMed ID: 22654103
[TBL] [Abstract][Full Text] [Related]
5. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
6. Enhanced activation of Ca2+/calmodulin-dependent protein kinase II upon downregulation of cyclin-dependent kinase 5-p35.
Hosokawa T; Saito T; Asada A; Ohshima T; Itakura M; Takahashi M; Fukunaga K; Hisanaga S
J Neurosci Res; 2006 Sep; 84(4):747-54. PubMed ID: 16802322
[TBL] [Abstract][Full Text] [Related]
7. Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator.
Endo R; Saito T; Asada A; Kawahara H; Ohshima T; Hisanaga S
J Biol Chem; 2009 Sep; 284(38):26029-39. PubMed ID: 19638632
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.
Kobayashi H; Saito T; Sato K; Furusawa K; Hosokawa T; Tsutsumi K; Asada A; Kamada S; Ohshima T; Hisanaga S
J Biol Chem; 2014 Jul; 289(28):19627-36. PubMed ID: 24872417
[TBL] [Abstract][Full Text] [Related]
9. S-nitrosylation-dependent proteasomal degradation restrains Cdk5 activity to regulate hippocampal synaptic strength.
Zhang P; Fu WY; Fu AK; Ip NY
Nat Commun; 2015 Oct; 6():8665. PubMed ID: 26503494
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine prevents beta-amyloid toxicity by a stimulatory effect on p35/cyclin-dependent kinase 5 activity in cultured cortical neurons.
Hsiao YH; Chen PS; Yeh SH; Lin CH; Gean PW
J Neurosci Res; 2008 Sep; 86(12):2685-95. PubMed ID: 18512759
[TBL] [Abstract][Full Text] [Related]
11. Quantitative measurement of in vivo phosphorylation states of Cdk5 activator p35 by Phos-tag SDS-PAGE.
Hosokawa T; Saito T; Asada A; Fukunaga K; Hisanaga S
Mol Cell Proteomics; 2010 Jun; 9(6):1133-43. PubMed ID: 20097924
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators.
Saito T; Yano M; Kawai Y; Asada A; Wada M; Doi H; Hisanaga SI
J Biol Chem; 2013 Nov; 288(45):32433-32439. PubMed ID: 24085300
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of drebrin by cyclin-dependent kinase 5 and its role in neuronal migration.
Tanabe K; Yamazaki H; Inaguma Y; Asada A; Kimura T; Takahashi J; Taoka M; Ohshima T; Furuichi T; Isobe T; Nagata K; Shirao T; Hisanaga S
PLoS One; 2014; 9(3):e92291. PubMed ID: 24637538
[TBL] [Abstract][Full Text] [Related]
14. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
[TBL] [Abstract][Full Text] [Related]
15. Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25.
Sato K; Minegishi S; Takano J; Plattner F; Saito T; Asada A; Kawahara H; Iwata N; Saido TC; Hisanaga S
J Neurochem; 2011 May; 117(3):504-15. PubMed ID: 21338355
[TBL] [Abstract][Full Text] [Related]
16. Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.
Xu J; Tsutsumi K; Tokuraku K; Estes KA; Hisanaga S; Ikezu T
J Neurochem; 2011 Jan; 116(2):192-204. PubMed ID: 20492361
[TBL] [Abstract][Full Text] [Related]
17. Involvement of cyclin dependent kinase 5 and its activator p35 in staurosporine-induced apoptosis of cortical neurons.
Zhang BF; Peng FF; Zhang W; Shen H; Wu SB; Wu DC
Acta Pharmacol Sin; 2004 Sep; 25(9):1105-11. PubMed ID: 15339383
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid downregulates Cdk5 activity via the transcription of the p35 mRNA.
Takahashi M; Ishida M; Saito T; Ohshima T; Hisanaga S
Biochem Biophys Res Commun; 2014 May; 447(4):678-82. PubMed ID: 24755075
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mutant Huntingtin aggregate formation by Cdk5/p35 through the effect on microtubule stability.
Kaminosono S; Saito T; Oyama F; Ohshima T; Asada A; Nagai Y; Nukina N; Hisanaga S
J Neurosci; 2008 Aug; 28(35):8747-55. PubMed ID: 18753376
[TBL] [Abstract][Full Text] [Related]
20. Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39.
Minegishi S; Asada A; Miyauchi S; Fuchigami T; Saito T; Hisanaga S
Biochemistry; 2010 Jul; 49(26):5482-93. PubMed ID: 20518484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
